Literature DB >> 18930721

Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase.

Ying-Zi Gong1, Wei-Guang Ding, Jie Wu, Keiko Tsuji, Minoru Horie, Hiroshi Matsuura.   

Abstract

In humans, Kv1.5 (hKv1.5) channels conduct the ultra-rapid delayed rectifier K(+) current (I(Kur)) that is important for the repolarization of cardiac action potentials. We aimed at examining the effect of lipoxygenase inhibitors cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate (CDC), nordihydroguaiaretic acid (NDGA), and gossypol on hKv1.5 wild-type and mutant channels heterologously expressed in Chinese hamster ovary (CHO) cells, by use of the site-directed mutagenesis and whole-cell patch-clamp method. CDC and NDGA, but not gossypol, a structurally dissimilar inhibitor, reversibly inhibited hKv1.5 current in a concentration-dependent manner with IC(50) of 5.7 microM and 16.4 microM, respectively. The blockade evoked by both drugs was voltage-dependent between -20 and +10 mV (voltage range of channel opening). Moreover, this blocking action was found to progress with time during depolarizing voltage steps with a more rapid block at higher concentrations. CDC induced slight but significant delay of the deactivation rate. However, NDGA markedly slowed the deactivation time course, resulting in a tail crossover phenomenon. The recovery time constants from current block at repolarizing potentials for CDC and NDGA were 60.9 ms and 129.7 ms, respectively. Mutation of arginine 487 to valine (R487V) in the outer pore region of the channel significantly reduced the CDC action. These results demonstrate for the first time that CDC and NDGA block hKv1.5 channels by binding to the open state of the channels, independently of their effects on lipoxygenase activity. The putative binding site for CDC appears to be related to arginine 487 located in the outer pore region.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930721     DOI: 10.1016/j.ejphar.2008.10.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  12/15-Lipoxygenase inhibition counteracts MAPK phosphorylation in mouse and cell culture models of diabetic peripheral neuropathy.

Authors:  Roman Stavniichuk; Alexander A Obrosov; Viktor R Drel; Jerry L Nadler; Irina G Obrosova; Mark A Yorek
Journal:  J Diabetes Mellitus       Date:  2013-08

2.  Putative binding sites for arachidonic acid on the human cardiac Kv 1.5 channel.

Authors:  Jia-Yu Bai; Wei-Guang Ding; Akiko Kojima; Tomoyoshi Seto; Hiroshi Matsuura
Journal:  Br J Pharmacol       Date:  2015-10-22       Impact factor: 8.739

3.  Regulation of human cardiac Kv1.5 channels by extracellular acidification.

Authors:  Shuang Wang; Wei-Guang Ding; Jia-Yu Bai; Futoshi Toyoda; Min-Jie Wei; Hiroshi Matsuura
Journal:  Pflugers Arch       Date:  2016-10-28       Impact factor: 3.657

4.  Waixenicin A inhibits cell proliferation through magnesium-dependent block of transient receptor potential melastatin 7 (TRPM7) channels.

Authors:  Susanna Zierler; Guangmin Yao; Zheng Zhang; W Cedric Kuo; Peter Pörzgen; Reinhold Penner; F David Horgen; Andrea Fleig
Journal:  J Biol Chem       Date:  2011-09-16       Impact factor: 5.157

5.  Systematic analysis of rat 12/15-lipoxygenase enzymes reveals critical role for spinal eLOX3 hepoxilin synthase activity in inflammatory hyperalgesia.

Authors:  Ann M Gregus; Darren S Dumlao; Spencer C Wei; Paul C Norris; Laura C Catella; Flore G Meyerstein; Matthew W Buczynski; Joanne J Steinauer; Bethany L Fitzsimmons; Tony L Yaksh; Edward A Dennis
Journal:  FASEB J       Date:  2013-02-04       Impact factor: 5.191

6.  Improved functional expression of human cardiac kv1.5 channels and trafficking-defective mutants by low temperature treatment.

Authors:  Wei-Guang Ding; Yu Xie; Futoshi Toyoda; Hiroshi Matsuura
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.